1. Home
  2. ANDG vs SLN Comparison

ANDG vs SLN Comparison

Compare ANDG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Andersen Group Inc. Class A Common Stock

ANDG

Andersen Group Inc. Class A Common Stock

N/A

Current Price

$66.70

Market Cap

1.3B

Sector

Real Estate

ML Signal

N/A

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

N/A

Current Price

$19.76

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANDG
SLN
Founded
2002
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2025
2010

Fundamental Metrics

Financial Performance
Metric
ANDG
SLN
Price
$66.70
$19.76
Analyst Decision
Buy
Hold
Analyst Count
8
5
Target Price
★ $61.29
$19.75
AVG Volume (30 Days)
411.5K
★ 4.3M
Earning Date
11-12-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $838,692,000.00
$559,000.00
Revenue This Year
$18.38
N/A
Revenue Next Year
$18.35
$131.31
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 14.64
N/A
52 Week Low
$18.12
$4.19
52 Week High
$68.41
$19.87

Technical Indicators

Market Signals
Indicator
ANDG
SLN
Relative Strength Index (RSI) 67.64 78.03
Support Level $52.10 $13.01
Resistance Level $68.41 $19.87
Average True Range (ATR) 2.53 0.07
MACD -0.14 -0.20
Stochastic Oscillator 73.93 55.81

Price Performance

Historical Comparison
ANDG
SLN

About ANDG Andersen Group Inc. Class A Common Stock

Andersen Group Inc is a provider of independent tax, valuation, and financial advisory services to individuals and family offices, businesses, and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services. The firm generates the key revenue from Private Client Services, which provide comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving, and trust and estate planning.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: